“SELF-SPREADING” VACCINES TAKE A DANGEROUS STEP FORWARD
If this goes ahead it could be "game over" for humanity
This is the most important and frankly, frightening item of information that I have seen and so far the only source seems to be the HIghwire.
I have on seen the following article from iCan, the Hightwire’s legal arm.
ICAN UNCOVERS A POTENTIAL NEXT-LEVEL THREAT: “INHALABLE” SELF-SPREADING VACCINES THAT SPREAD LIKE A VIRUS
A new class of “encrypted RNA” vaccines are being developed where the RNA would piggyback onto an existing wild virus and spread from person to person without any person’s knowledge or consent. Although this may sound like science fiction, it is far from it. Two companies involved in this research have received millions of dollars from the federal government. A study using this technology on hamsters and the SARS-Cov-2 virus has already been completed and a Phase I trial on humans is in the works. ICAN’s attorneys have already sent legal demands to all government agencies involved.
It seems the government and the military are so enthused about this new vaccine deployment technology that Congress tucked a law, the PREVENT Pandemics Act, into the 2023 omnibus appropriations bill to facilitate it. Among other things, the Act has a section dedicated to Platform Technologies that supports the “development and review of new treatments and countermeasures that use cutting-edge, adaptable platform technologies that can be incorporated or used in more than one drug or biological product.”
This Act will also be used to fund a new HHS government agency called ARPA-H (Advanced Research Projects Agency for Health), which was created in 2023 to “take big technical risks that can spark new biomedical breakthroughs” and “revolutionize the detections, diagnosis, mitigation, prevention, treatment and cure of diseases and health conditions.” Both former NIH Director Francis Collins and HHS Secretary Xavier Becerra supported the agency’s creation, and Collins described his vision for ARPA-H as “a DARPA-like culture at NIH.”
This so-called “therapy” uses a technology called TIPs (Therapeutic Interfering Particles), which are described as “engineered molecular parasites” that piggyback on a wild virus. If you get the virus, you also get these parasites. Once inside an infected person, the TIPs are supposed to rapidly multiply, hijacking the resources the wild virus needs to multiply and therefore stopping the virus.
Supporters of this technology claim it will “solve” several problems with traditional vaccine delivery, including “behavior barriers” like noncompliance. Meaning everyone gets vaccinated—whether they like it or not.
One of the companies developing this technology is Autonomous Therapeutics, led by Dr. Ariel Weinberger. Autonomous has received over $15 million in federal government contracts and grants, including an ongoing $4.58 million award from DARPA (a Department of Defense agency) for “A Rapid-Response Platform to Develop & Deliver TIPs Against Respiratory Viral Threats, Including MERS-CoV” and a $3 million contract from DARPA for “New Platform Technologies for Viral and Therapeutic Evolution Assays” that was completed in 2022. Dr. Timothy Notton is the Chief Scientific Officer at Autonomous and his bio references his work on “automated screening platforms (inhalable) LNP delivery platforms.”
In a recent article, Ariel gushes:
This next-generation RNA, which we aim to advance at Autonomous Therapeutics Inc., is designed to encode an artificial immune system that can detect and eliminate every variant of a viral family. We have developed encrypted RNA candidates with potential variant-proof efficacy against a wide range of pathogens, from coronaviruses to influenza and RSV. These can be made inhalable and shielded from human immune systems to enable safe and long-term prophylaxis. (Emphasis added.)
The other company working on similar vaccines, VxBiosciences, appears to collaborate with the J. David Gladstone Institutes, led by Dr. Leor Weinberger—who happens to be Ariel’s brother. Patents are already established, such as this one by Leor and Gladstone Institutes in 2017. In a 2020 TEDMED talk, Leor talked about how using viruses would “convert super-spreaders from spreading the virus to spreading the therapy.”
HHS issued a $4.8 million grant to VxBiosciences for “Autonomously Deploying, Co-evolving SARS-CoV-2 Antiviral.” The grant was for engineering “therapeutic molecular parasites of SARS-CoV-2 that can co-adapt and transmit among infected hosts … acting as single-administration therapies that circumvent compliance issues.”
So, how safe are these “inhalable therapies”? What could possibly go wrong with a man-made parasite designed to self-replicate in your cells and to transmit without anyone’s knowledge or consent? Your guess is as good as ours. But we’d prefer not to find out.
Through its attorneys, ICAN has already submitted numerous FOIA requests to DARPA, DOI, the Navy, and NIH concerning these grants and contracts to ascertain the truth about who stands to benefit from these alarming products……
This item on the Highwire discusses this in detail
“SELF-SPREADING” VACCINES TAKE A DANGEROUS STEP FORWARD
Watch HERE
This is how Del Bigtree frames it (from the above video)
He goes on
Here are some of the articles referred to.
Abstract
Infectious disease control faces significant challenges including: how to therapeutically target the highest-risk populations, circumvent behavioral barriers, and overcome pathogen persistence and resistance mechanisms. We review a recently proposed solution to overcome these challenges: antivirals that transmit by 'piggybacking' on viral replication. These proposed antivirals, termed 'therapeutic interfering particles' (TIPs), are engineered molecular parasites of viruses that are designed to steal replication resources from the wild type virus. Depriving viruses of crucial replication machinery, TIPs would reduce viral loads. As obligate parasites, TIPs would transmit via the same risk factors and transmission routes as wild type viruses, automatically reaching high-risk populations, and thereby substantially limiting viral transmission even in resource-poor settings. Design issues and ethical/safety considerations of this proposed intervention are discussed.
https://pubmed.ncbi.nlm.nih.gov/25017994/
From DARPA
https://www.darpa.mil/news-events/2016-04-07a
DARPA Seeks First-in-Human Therapeutic Interfering Particles Targeting Respiratory Viruses
The Defense Advanced Research Projects Agency (DARPA) Small Business Programs Office is seeking innovative research concepts for Therapeutic Interfering Particles (TIPs) as a medical countermeasure against viruses in humans.
There is a critical DoD need to respond effectively to rapidly evolving viruses against which vaccines and therapeutics are intrinsically difficult to develop. TIPs are virus-derived particles lacking pathogenic genetic components and engineered to outcompete the virus for the viral components required for replication. As virus-derived particles, TIPs have the potential to co-evolve and keep pace with evolving pathogens.
By out-competing the virus, TIPs can directly reduce the number of infectious viruses within a patient and attenuate disease transmission. These properties make TIPs especially well-suited to combating rapidly evolving pathogens. Although these attributes have been demonstrated in the literature, in vitro, and in vivo, their safety and efficacy have yet to be shown in humans.
In particular, DARPA is interested in understanding the feasibility of Phase I Clinical Trials for TIPs. DARPA seeks to de-risk this emerging technology through a small, first-in-human Phase I clinical trial.
For this effort, DARPA will accept proposals for cost up to $2,250,000. This includes a 24-month base period not to exceed a cost of $2,000,000 and a separately priced option of up to $250,000 for participation in the DARPA Entrepreneurial Investigator Initiative.
This solicitation will open for proposals on June 5, 2019 and close on July 3, 2019.
Additional details are available via Solicitation Number: HR001119S0035-02
References
Dimmock NJ, Easton, AJ. Defective Interfering Influenza Virus RNAs: Time To Reevaluate Their Clinical Potential as Broad-Spectrum Antivirals? Journal of Virology. 2014 May; 88(10): 5217-5227.
Smith SM, Scott PD, O’Callaghan C, Easton AJ, Dimmock NJ. A Defective Interfering Influenza RNA Inhibits Infectious Influenza Virus Replication in Human Respiratory Tract Cells: A Potential New Human Antiviral. Viruses. 2016 Aug; 8(8) 237
This shows the official government interest
Abstract
Viral-deletion mutants that conditionally replicate and inhibit the wild-type virus (i.e., defective interfering particles, DIPs) have long been proposed as single-administration interventions with high genetic barriers to resistance. However, theories predict that robust, therapeutic DIPs (i.e., therapeutic interfering particles, TIPs) must conditionally spread between cells with R0 >1. Here, we report engineering of TIPs that conditionally replicate with SARS-CoV-2, exhibit R0 >1, and inhibit viral replication 10- to 100-fold. Inhibition occurs via competition for viral replication machinery, and a single administration of TIP RNA inhibits SARS-CoV-2 sustainably in continuous cultures. Strikingly, TIPs maintain efficacy against neutralization-resistant variants (e.g., B.1.351). In hamsters, both prophylactic and therapeutic intranasal administration of lipid-nanoparticle TIPs durably suppressed SARS-CoV-2 by 100-fold in the lungs, reduced pro-inflammatory cytokine expression, and prevented severe pulmonary edema. These data provide proof of concept for a class of single-administration antivirals that may circumvent current requirements to continually update medical countermeasures against new variants.
https://pubmed.ncbi.nlm.nih.gov/34838159/
This is the face behind all this, Leor Weinberger
In 2016
Engineering Our Way to Next Generation Therapies
In 2020, and he is declaring victory over Creation
Can we create vaccines that mutate and spread?
Watch HERE
It has reached the level of government
HHS issued a $4.8 million grant to VxBiosciences for “Autonomously Deploying, Co-evolving SARS-CoV-2 Antiviral.” The grant was for engineering “therapeutic molecular parasites of SARS-CoV-2 that can co-adapt and transmit among infected hosts … acting as single-administration therapies that circumvent compliance issues.”
It has been incorporated into US government legislation
It seems the government and the military are so enthused about this new vaccine deployment technology that Congress tucked a law, the PREVENT Pandemics Act, into the 2023 omnibus appropriations bill to facilitate it. Among other things, the Act has a section dedicated to Platform Technologies that supports the “development and review of new treatments and countermeasures that use cutting-edge, adaptable platform technologies that can be incorporated or used in more than one drug or biological product.”
Prevent Pandemics Act 2022
What can go wrong?
This is from no less than the World Economic Forum, albeit from back in 2015.
Read the article HERE
I’ve been concerned about this for quite some time. Thank you for the comprehensive article!
My question always is - how do “they” protect themselves from this and all of the other havoc they’re causing? The food supply, medicines, technocracy, crime, chaos, etc. Are they such staunch believers, or are they so arrogant they think they’ll be able to be immune?
Look for ARPA I saw this the other day